InsiderPulse| Date | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Young David | Director & Pres. Research & Development | Purchase | 1,706 | $2.69 | $5K | 13.8K | View ↗ | |
| 2026-04-30 | SKIBSTED RUSSELL | Chief Financial Officer | Purchase | 2,190 | $2.69 | $6K | 6,498 | View ↗ | |
| 2026-04-15 | Young David | Director & Pres. Research & Development | Purchase | 1,545 | $2.97 | $5K | 12.1K | View ↗ | |
| 2026-04-15 | Ng George K | Director & Chief Executive Officer | Purchase | 1,843 | $2.97 | $5K | 5,492 | View ↗ | |
| 2026-04-15 | Lin Patrick | Chief Business - Strategy Off | Purchase | 1,369 | $2.97 | $4K | 4,725 | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Research and development expenses | $7.8M+7.4% | $7.3M+25.3% | $5.8M-49.5% | $11.5M |
| General and administrative expenses | $6.2M+29.2% | $4.8M-15.5% | $5.7M-35.4% | $8.8M |
| Operating Loss | -$14.0M-16.1% | -$12.1M-5.2% | -$11.5M+58.4% | -$27.5M |
| Other income | $20K | — | — | — |
| Unrealized gain on digital assets at fair value | $295K | — | — | — |
| Interest and dividend income, net | $109K-45.6% | $201K | — | — |
| Net Operating Loss Before Income Tax Benefit | -$13.6M-14.5% | -$11.9M-6.6% | -$11.1M+59.4% | -$27.4M |
| Net Loss | -$13.6M-14.5% | -$11.9M-6.6% | -$11.1M+59.4% | -$27.4M |
| Net Loss Per Common Share - Basic | -$10.36+89.3% | -$96.78-1041.3% | -$8.48+75.1% | -$34.05 |
| Net Loss Per Common Share - Diluted | -$10.36+89.3% | -$96.78-1041.3% | -$8.48+75.1% | -$34.05 |
| Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Basic | $1.3M+969.3% | $122K-90.7% | $1.3M+62.8% | $805K |
| Weighted Average Common Shares Used to Compute Net Loss Per Common Shares - Diluted | $1.3M+969.3% | $122K-90.7% | $1.3M+62.8% | $805K |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Processa Pharmaceuticals to Attend 44th Annual J.P. Morgan Healthcare Conference
Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Processa Pharmaceuticals Completes Enrollment of 20th Patient for Formal Interim Analysis in Phase 2 NGC-Cap Breast Cancer Study
Processa Pharmaceuticals and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV